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Abstract: Approximately 25% of the adult population worldwide is hypertensive and thus at 
risk of cardiovascular morbidity and mortality. Despite the availability of many antihypertensive 
drugs, at least 50% of patients do not achieve blood pressure (BP) targets and thus remain at 
increased cardiovascular risk. Fixed-dose (FD) irbesartan/hydrochlorothiazide (HCTZ) is an 
antihypertensive combination therapy approved for the treatment of patients whose BP is not 
adequately controlled on monotherapy and for initial treatment of patients likely to need mul-
tiple drugs to achieve their BP goal. The efﬁ  cacy and tolerability of FD irbesartan/HCTZ has 
been demonstrated in both patient populations in large multicenter studies. In patients failing 
antihypertensive monotherapy, FD irbesartan/HCTZ (150/12.5 mg) has been shown to be more 
effective than FD valsartan/HCTZ (80/12.5 mg) and at least comparable to FD losartan/HCTZ 
(50/12.5 mg). In patients with moderate or severe hypertension receiving FD irbesartan/HCTZ 
as initial therapy, this combination achieved more rapid BP reductions compared with irbesartan 
monotherapy and enabled a greater proportion of patients with severe hypertension to achieve 
their BP target. FD irbesartan/HCTZ is thus a valuable addition to the clinician’s armamentarium 
for the management of hypertension and should help more patients achieve their BP target.
Keywords: blood pressure control, blood pressure target, combination therapy, angiotensin 
receptor blockers
Management issues in treating hypertension
Hypertension is a major cause of morbidity and mortality and an important public 
health challenge worldwide. It has been estimated that hypertension is responsible 
for approximately two-thirds of all strokes and 50% of heart attacks worldwide.1 
In addition, hypertension causes 7.1 million premature deaths per year worldwide 
and is responsible for 4.5% of the global burden of disease.1 This startling impact of 
hypertension on health worldwide in part reﬂ  ects the high prevalence of hypertension. 
According to a recent review of published literature, approximately a quarter of the 
adult population worldwide (26.4%) was hypertensive in 2000 and this is expected to 
increase to 29.2% by 2025.2 Appropriate management of hypertension is therefore an 
important priority worldwide, especially given the impact that effective blood pressure 
(BP) control can have on morbidity and mortality.
Effective BP control has been shown to signiﬁ  cantly reduce morbidity and mortality, 
as demonstrated in a meta-analysis of data from trials of active antihypertensive treatment 
compared with placebo.3 According to this analysis, active antihypertensive treatment 
in hypertensive patients signiﬁ  cantly reduced the risk of fatal and nonfatal stroke by 
approximately 40% and coronary heart disease (CHD) by approximately 15%, while 
all-cause mortality was reduced by approximately 15% and cardiovascular mortality by 
approximately 20%. In addition, a meta-analysis of data from 61 prospective observa-
tional studies has shown that the risk of vascular mortality is strongly and directly related Vascular Health and Risk Management 2009:5 214
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to BP in middle-aged and elderly individuals. A 2-mmHg 
reduction in systolic blood pressure (SBP) has been reported 
to result in a 7% reduction in the risk of ischemic heart disease 
and a 10% reduction in the risk of stroke mortality, while 
larger reductions in SBP produce even greater reductions in 
vascular morbidity and mortality.4 These data provide a strong 
rationale for the use of antihypertensive therapy to reduce the 
burden of morbidity and mortality associated with this highly 
prevalent condition.
However, despite the availability of a large number of 
antihypertensive agents, BP control remains inadequate in 
many patients. For example, a study which analyzed data 
collected in surveys conducted in the 1990s reported rates of 
BP control ranging from 5% to 10% in European countries, 
17% in Canada and 29% in the US.5 More recently, Wang 
et al6 reported rates of BP control of 27% to 40% in ﬁ  ve 
European countries (France, Germany, Italy, Spain, the UK) 
and 53% in the US, suggesting that rates of BP control are 
improving. However, over half of patients still fail to reach 
BP targets, and are therefore at increased risk of cardiovas-
cular morbidity and mortality. It is mainly SBP targets that 
are not reached7 and systolic hypertension is most frequent 
in the elderly.8 It has recently been suggested that control of 
SBP alone should be the guide to treatment.9
Poor patient compliance with antihypertensive therapy 
and circumstances that do no allow physicians to adhere to 
treatment guidelines are frequent problems and are often the 
reason for patients not reaching their BP goal. For example, 
a recent survey of primary care physicians in 17 countries 
worldwide reported that 72% of physicians said that patients 
are not compliant with antihypertensive treatment when asked 
why over 50% of patients fail to achieve their BP targets.10 
A US study of patients receiving free medical care found that 
fewer than a third of patients on antihypertensive medication 
were still taking their prescribed medication a year later.11 
Another study investigating the rate of discontinuation or 
change in antihypertensive therapy in patients newly pre-
scribed a course of antihypertensive medication has reported 
that 50% to 60% of patients discontinue or change therapy 
within 6 months.12 Improving compliance is therefore an 
important task for all healthcare providers.13 An important 
move to overcome this issue has been the development of 
ﬁ  xed-dose (FD) combination therapies, since most patients 
require combination therapy to achieve BP targets.14
Fixed-dose combinations
Most guidelines suggest that initial combination treatment 
should include a thiazide diuretic and either an angiotensin 
receptor blocker (ARB), an angiotensin-converting enzyme 
inhibitor (ACE-I), a calcium channel blocker (CCB), or a 
beta-blocker.14,15 In addition, for patients with chronic renal 
disease or type 2 diabetes, combinations including an ARB or 
ACE-I are recommended.15–20 FD combinations are now avail-
able consisting of combinations of different antihypertensive 
drugs which ﬁ  t these recommendations, including: an ARB 
plus a thiazide diuretic; an ARB plus a calcium antagonist, an 
ACE inhibitor plus a thiazide diuretic; a beta-blocker with a 
diuretic; and an ACE inhibitor plus a calcium antagonist.14
The usefulness of FD ARB/hydrochlorothiazide (HCTZ) 
combinations in effectively treating hypertension, includ-
ing difﬁ  cult-to-treat and severely hypertensive patients, has 
been demonstrated for several different ARBs.14 Promising 
results have also been reported for FD combinations regard-
ing improvements in clinical endpoints, as well as achieving 
BP targets.
There is evidence to suggest that combination therapy 
can be better tolerated than certain monotherapies. The use 
of low-dose combination therapy is associated with fewer 
adverse events than with the higher doses of single agents that 
would be required to achieve the same level of BP control.21 
In addition, combining HCTZ with an ARB attenuates 
the hypokalemic and fasting glucose-modifying effects of 
HCTZ.22 As discussed in a later section, there is evidence to 
suggest that FD combinations are also associated with better 
compliance.23–25
In the recent ACCOMPLISH study (Avoiding Cardio-
vascular Events in Combination Therapy in Patients Living 
with Systolic Hypertension), HCTZ was compared with 
amlodipine on the basis of benazepril treatment in patients 
with compelling indications for the use of CCBs (eg, any 
atherosclerotic disease). Patients with a compelling indica-
tion for the use of HCTZ (eg, heart failure) were excluded. 
Cardiovascular morbidity and mortality were reduced by 
20% with the ACE-I/CCB combination.26 In addition, in this 
study, BP control rates were 75% in the ACE-I/CCB arm 
and 72% in the ACE-I/HCTZ arm. These BP control rates 
are better than those reported in other recent major trials in 
hypertensive patients.26 The study design may have favored 
the ACE-I/CCB arm as the primary endpoint included 
measures of myocardial ischemia in which CCBs are more 
effective and excluded heart failure in which diuretics are 
more effective.14,18,26
FD combinations of benazepril/HCTZ and benazepril/
amlodipine have been reported to significantly reduce 
BP and albuminuria (p   0.0001), in patients with type 2 
diabetes and mild hypertension, although a signiﬁ  cantly Vascular Health and Risk Management 2009:5 215
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greater reduction in albuminuria was achieved with the ACE 
inhibitor/HCTZ combination.27 In another study, the com-
bination of trandolapril/verapamil was found to be superior 
to losartan/HCTZ in reducing new-onset diabetes in patients 
with hypertension and impaired glucose tolerance titrated to 
achieve a SBP of  130 mmHg; the incidence of new-onset 
diabetes was 11.0% for trandolapril/verapamil vs 26.6% for 
losartan/HCTZ (p = 0.002).28
FD ARB/CCB combinations (amlodipine with either 
olmesartan or valsartan) are also effective in treating hyper-
tension.29,30 BP control rates of 74% have been reported after 
16 weeks of valsartan/amlodipine 160/10 mg treatment,29 and 
of 53% after 8 weeks of olmesartan/amlodipine 20/10 mg 
treatment.30 Combining a CCB with an ARB may reduce 
the incidence of peripheral edema as seen with olmesartan/
amlodipine compared with amlodipine alone:30 the incidence 
of edema was reduced from 13.0% to 36.8% for amlodipine 
monotherapy (dose range 5–10 mg) to 18.0% to 26.5% 
when olmesartan was combined with amlodipine (dose 
range 10/5 mg-40–10 mg), and was lowest for olmesartan 
monotherapy (dose range 10–40 mg, 9.9%–18.5%).
This review focuses on the beneﬁ  ts and tolerability of the 
FD ARB/HCTZ combination of irbesartan/HCTZ.
Overview of pharmacology, mode 
of action, and pharmacokinetics 
of irbesartan and HCTZ, alone 
and in combination
A valuable FD combination therapy that has received 
approval in Europe and the US is FD irbesartan/HCTZ. FD 
irbesartan/HCTZ is approved for the treatment of patients 
whose BP is not adequately controlled on irbesartan or HCTZ 
alone (US and European license),31,32 and in the US (but not 
in Europe) for initial treatment of patients likely to need mul-
tiple drugs to achieve their BP goals.31 FD irbesartan/HCTZ 
is available as 150/12.5 mg, 300/12.5 mg and 300/25 mg and 
therapy should be started with the low dose and uptitrated. 
This paper reviews the efﬁ  cacy and safety data for FD 
irbesartan/HCTZ, both for patients inadequately controlled 
on antihypertensive monotherapy and as initial therapy for 
patients with moderate or severe hypertension.
FD irbesartan/HCTZ has been developed in response 
to promising results reported for combination therapy with 
both agents given as individual tablets, as discussed in 
later sections of this paper,22,33,34 and the fact that combining 
irbesartan and HCTZ is a logical option for patients requiring 
combination therapy since the 2 agents act via distinct 
mechanisms of action. Irbesartan exerts its antihypertensive 
effects by inhibiting the activation of angiotensin II type 1 
(AT1) receptors. This elicits vasodilation and reduces the 
secretion of vasopressin and aldosterone, thereby reducing 
BP. HCTZ is a thiazide diuretic. It exerts its antihypertensive 
effects by inhibiting Na+/Cl− reabsorption from the distal 
convoluted tubules in the kidney. By reducing osmotic pres-
sure in this way, HCTZ reduces the reabsorption of water 
in the distal convoluted tubules and thereby reduces plasma 
volume and cardiac output. The combined effect of these 
actions is to reduce BP.
Both irbesartan and HCTZ are active following oral 
administration and do not require biotransformation. They 
are efﬁ  ciently absorbed following oral administration, having 
an oral bioavailability of 60% to 80% (irbesartan) and 50% 
to 80% (HCTZ), and peak concentrations are reached 1.5 to 
2 hours (irbesartan) and 1 to 2.5 hours (HCTZ) after admin-
istration.32 The intake of food does not affect the bioavail-
ability of either agent.
Irbesartan exhibits linear dose-proportional pharmaco-
kinetics over the dose range 10 to 600 mg. Repeated dosing 
results in limited accumulation ( 20%) and steady state 
concentrations are achieved within 3 days with once-daily 
administration.35 Irbesartan is largely excreted unchanged 
(80%–85%), but is also metabolized in the liver via glucuro-
nide conjugation and oxidation. Irbesartan and its metabolites 
are eliminated largely in the feces (80%) but also in the urine 
(20%). Its terminal elimination half-life is 11 to 15 hours, 
which compares favorably with most other ARBs.36
Pharmacokinetic data on the irbesartan/HCTZ combina-
tion are not available but co-administration of irbesartan 
and HCTZ has no effect on the pharmacokinetics of either 
drug,37 but increases the BP lowering activity observed,32 as 
discussed further in the following section of this review.
Efﬁ  cacy of FD irbesartan/HCTZ 
combination
The beneﬁ  ts of combining irbesartan and HCTZ were demon-
strated in an early study using a matrix design to investigate 
the effects of combinations of different doses of irbesartan 
(0, 37.5, 100 or 300 mg) plus HCTZ (0, 6.25, 12.5 or 25 mg) 
on BP.22 The reduction in DBP by 8 weeks ranged from 
3.5 mmHg for placebo, to 5.1 to 8.3 mmHg for HCTZ mono-
therapy, 7.1 to 10.2 mmHg for irbesartan monotherapy, and 
8.1 to 15.0 mmHg for combination therapy, clearly indicating 
a synergistic effect for the addition of irbesartan to HCTZ 
and vica versa. Similarly, the proportion of responders (ie, 
patients achieving normalized DBP or trough DBP decreased Vascular Health and Risk Management 2009:5 216
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by  10 mmHg) at 8 weeks increased from 24% for placebo, 
to 36% to 53% for HCTZ monotherapy, 35% to 58% for 
irbesartan monotherapy, and 44% to 80% for combination 
therapy.
FD irbesartan/HCTZ in patients failing 
on antihypertensive monotherapy
The beneﬁ  ts of FD irbesartan/HCTZ combination therapy 
have subsequently been demonstrated in a number of trials 
in patients with mild hypertension who failed to achieve BP 
control with monotherapy, and in patients with moderate or 
severe hypertension. The efﬁ  cacy data for the main studies 
are summarized in Table 1.
The efﬁ  cacy of FD irbesartan/HCTZ 300/25 mg was ﬁ  rst 
demonstrated in a study of hypertensive patients who had 
failed to gain BP control after at least 2 months of high-dose 
monotherapy or low-dose combination therapy.38 In this 
study, 57 patients with SBP/DBP  140/90 mmHg received 
FD irbesartan/HCTZ 300/25 mg once daily for 12 weeks. 
A signiﬁ  cant reduction in clinic and ambulatory mean BP 
was observed at the end of the study period compared with 
baseline. Mean 24-hour SBP was reduced from 146.0 to 
123.3 mmHg and mean 24-hour DBP was reduced from 89.8 
to 76.5 mmHg, both differences were statistically signiﬁ  cant 
(p   0.001). In addition, therapy achieved a mean lowering 
of ambulatory SBP/DBP at peak of 25.2/14.7 mmHg and 
22.3/12.3 mmHg at trough. Thus FD irbesartan/HCTZ was 
found to produce clinically meaningful reductions in SBP/
DBP in patients failing to achieve BP targets on monotherapy 
or low-dose combination therapy.
FD irbesartan/HCTZ at the lower dose of 150/12.5 mg has 
shown superior efﬁ  cacy to other ARB/HCTZ combinations 
in comparative trials. The COmparative Study of Efﬁ  cacy of 
Irbesartan/HCTZ with Valsartan/HCTZ Using Home Blood 
Pressure Monitoring in the TreAtment of Mild-to-Moderate 
Hypertension (COSIMA) study, compared the BP-lowering 
effects of irbesartan/HCTZ 150/12.5 mg and FD valsartan/
HCTZ 80/12.5 mg.39 Patients (n = 800) with untreated or 
uncontrolled mild-to-moderate essential hypertension ini-
tially received HCTZ 12.5 mg for 5 weeks. 464 patients 
failing to achieve BP control (SBP   140 mmHg) at the 
end of this period were randomized to receive FD irbesartan/
HCTZ 150/12.5 mg or FD valsartan/HCTZ 80/12.5 mg once 
daily for 8 weeks. Effects on BP were assessed by both 
ofﬁ  ce BP measurements and home BP monitoring (HBPM). 
Irbesartan/HCTZ produced greater reductions in both ofﬁ  ce 
and home BP compared with valsartan/HCTZ over the treat-
ment period; according to HBPM a reduction in SBP of 
13.0 mmHg was achieved with irbesartan/HCTZ compared 
with 10.6 mmHg with valsartan/HCTZ (p = 0.0094), while 
the reduction in DBP achieved was 9.5 mmHg for irbesartan/
HCTZ compared with 7.4 mmHg for valsartan/HCTZ 
(p = 0.0007). In addition, the BP normalization rate (SBP/
DBP   135/85 mmHg) according to HBPM was signiﬁ  cantly 
greater with irbesartan/HCTZ than with valsartan/HCTZ 
(50.2% vs 33.2%, p = 0.0003).
FD irbesartan/HCTZ 150/12.5 mg has also been shown to 
be more efﬁ  cacious than FD losartan/HCTZ 50/12.5 mg.40 In 
this study, patients with mild-to-moderate hypertension were 
randomized to receive FD irbesartan/HCTZ 150/12.5 mg 
(n = 16) or FD losartan/HCTZ 50/12.5 mg (n = 15) for 
4 weeks. While both treatments signiﬁ  cantly reduced BP from 
baseline, the reduction in ambulatory DBP was signiﬁ  cantly 
greater with irbesartan/HCTZ than with losartan/HCTZ; the 
adjusted mean change from baseline in 24-hour ambulatory 
DBP was −10.5 mmHg with irbesartan/HCTZ compared 
Table 1 Summary of efﬁ  cacy data for main studies of ﬁ  xed-dose irbesartan/hydrochlorothiazide (HCTZ)
Study Patients, n Duration of therapy and 
irbesartan/HCTZ dose
Mean reduction in 
SBP/DBP, mmHg
SBP/DBP normalization 
rate, %
Bobrie et al39 Failing monotherapy, 
n = 464
8 weeks; 150/12.5 mg 13.0/9.5 vs 10.6/7.4 for 
valsartan/HCTZ, p   0.01a
50.2 vs 33.2 for valsartan/
HCTZ, p = 0.0003 b
INCLUSIVE41 Failing monotherapy, 
n = 844
18 weeks; titrated to 300/25 mg 21.5/10.4 (p   0.001 vs 
baseline)
69c
Neutel et al46 Severe hypertension, 
n = 695
5 weeks; titrated to 300/25 mg 34.6 vs 19.2 for irbesartan 
monotherapy, p   0.0001d
Neutel et al48 Moderate hypertension, 
n = 538
8 weeks; titrated to 300/25 mg 27.1/14.6 vs 22.1/11.6 for 
irbesartan monotherapy, 
p   0.005
53.4 vs 40.6 for irbesartan 
monotherapy, p = 0.0254d
Notes: aSBP/DBP reduction according to home BP monitoring. bSBP/DBP normalization  135/85 mmHg. cSBP/DBP normalization  140/90 mmHg or 130/80 mmHg for 
patients with diabetes. dSBP/DBP normalization  140/90 mmHg.Vascular Health and Risk Management 2009:5 217
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with −6.1 mmHg with losartan/HCTZ, (p = 0.001). There was 
also a non-signiﬁ  cant trend towards a greater reduction in mean 
24-hour ambulatory SBP with irbesartan/HCTZ (−16.0 vs 
−11.1 mmHg). The response rate (ie, percentage of patients 
achieving a mean 24-hour ambulatory DBP of  90 mmHg or 
a reduction in mean 24-hour ambulatory DBP of   10 mmHg) 
was slightly higher for FD irbesartan/HCTZ but the difference 
was not statistically signiﬁ  cant (86.7% vs 80.0%).
The Irbesartan/Hydrochlorothiazide Blood Pressure 
Reductions in Diverse Patient Populations (INCLUSIVE) 
trial, extended the ﬁ  ndings of previous irbesartan/HCTZ trials 
by evaluating the efﬁ  cacy of low and high FD irbesartan/
HCTZ in a broad range of patients, including many in which 
BP goal attainment is particularly challenging, for example, 
the elderly, African Americans, and patients with type 2 
diabetes mellitus and/or metabolic syndrome.41 This was a 
large multicenter prospective open-label single-arm study. 
844 patients with uncontrolled SBP (140–159 mmHg or 
130–159 mmHg for patients with type 2 diabetes) on anti-
hypertensive monotherapy were recruited from 119 centers 
in the USA. Patients initially discontinued previous anti-
hypertensive therapy and received placebo for 4–5 weeks. 
They then received HCTZ 12.5 mg for 2 weeks followed 
by FD irbesartan/HCTZ 150/12.5 mg for 8 weeks and FD 
irbesartan/HCTZ 300/25 for 8 weeks (ie, active treatment was 
given for a total of 18 weeks). Changes in BP were assessed 
over the period of active treatment, ie, 18 weeks.
Over the course of the study, the mean reductions in SBP 
and DBP were 21.5 and 10.4 mmHg, respectively, and both 
were statistically signiﬁ  cant (p   0.001). At Week 18, mean 
SBP/DBP was 132.9 ± 13.8/81.1 ± 9.7 mmHg. In addition, 
77% of patients achieved their SBP goal ( 140 mmHg 
or  130 mmHg for patients with type 2 diabetes), 83% 
achieved their DBP goal ( 90 mmHg or  80 mmHg for 
patients with type 2 diabetes), and 69% achieved SBP and 
DBP goals. Thus over three-quarters of patients previously 
uncontrolled on monotherapy achieved SBP and/or DBP 
control with FD irbesartan/HCTZ (Table 1).
Several subgroup analyses of the INCLUSIVE data 
have conﬁ  rmed the efﬁ  cacy of the treatment regimen in 
patients whose hypertension is often difﬁ  cult to control. Of 
the patients included in this study, 30% (n = 254) had type 
2 diabetes, 46% (n = 386) had metabolic syndrome (MS) 
and 21% (n = 177) had both MS and type 2 diabetes. A sub-
group analysis of patients with type 2 diabetes (n = 227) 
found that the mean change from baseline in SBP/DBP for 
this subgroup was −18.2/−8.7 mmHg.42 This reduction was 
only slightly less than for the total study population and was 
statistically signiﬁ  cant compared with baseline (p   0.001). 
In addition, 56% of diabetes patients achieved their SBP goal 
of 130 mmHg, 63% achieved their DBP goal of 80 mmHg, 
and 40% achieved both SBP and DBP goals. Analysis of 
data for the subgroup of patients with MS (n = 345) yielded a 
similar reduction in BP compared with the total study popula-
tion (change from baseline in SBP/DBP, −21.0/−10.4 mmHg) 
and both were statistically signiﬁ  cant (p   0.001). In this 
subgroup, 73% achieved the SBP goal, 77% achieved the 
DBP goal and 61% achieved both SBP and DBP goals. For 
patients with both MS and type 2 diabetes (n = 157), 57% 
achieved the SBP goal, 59% the DBP goal and 39% reached 
both SBP and DBP goals. Thus FD irbesartan/HCTZ was 
found to achieve SBP goals in approximately three-quarters 
of patients with MS and over half of patients with type 2 
diabetes, despite the more stringent BP goals in patients with 
type 2 diabetes.42 BP control is particularly important for 
these patients who are at increased cardiovascular risk.
The possible impact of race/ethnicity and age on the 
response to FD irbesartan/HCTZ was also assessed.43,44 
While almost two-thirds of patients in the INCLUSIVE 
trial were Caucasian (n = 515, 61%), almost a quarter were 
African American (n = 191, 23%) and 14% (n = 119) were 
Hispanic/Latino. Mean changes in SBP/DBP were similar for 
all subgroups and were statistically signiﬁ  cant compared with 
baseline (p   0.001). The percentages of patients achieving 
SBP/DBP goals were also similar for the different racial/
ethnic subgroups: Caucasian, 70%; African-American, 66%; 
Hispanic/Latino, 65%.43 A quarter of patients included in the 
study were elderly (aged 65 years or older, n = 212, 25%).44 
Analysis of data for this subgroup showed that the mean 
reductions in SBP and DBP achieved were similar to those in 
the total study population (23.0/10.9 mmHg; p   0.001). At 
the end of the study, mean SBP/DBP was 134.0 ± 14.7/75.1 ± 
8.4 mmHg, and dual SBP/DBP goals were achieved in 72% 
of patients. This response rate is similar to that achieved in 
the total study population (69%) and shows that FD irbesar-
tan/HCTZ is highly efﬁ  cacious in elderly as well as younger 
patients. A secondary analysis of data from the INCLUSIVE 
study found that higher baseline SBP, female sex, type 2 
diabetes, and statin therapy were predictive of additional 
BP-lowering, suggesting that FD irbesartan/HCTZ may be a 
particularly appropriate choice of therapy in such patients.45
FD irbesartan/HCTZ as initial therapy 
in moderate or severe hypertension
As patients with moderate or severe hypertension are 
likely to require 2 or more antihypertensive medications to Vascular Health and Risk Management 2009:5 218
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attain BP goal, there is a clear rationale for treatment with 
combination therapy from the outset. The value of initial 
FD irbesartan/HCTZ in patients with moderate or severe 
hypertension has been investigated in 2 large multicenter 
studies, the RAPiHD moderate and severe trials.
The RAPiHD severe study, a randomized, double-blind, 
active-control, multicenter study, investigated the efﬁ  cacy 
of FD irbesartan/HCTZ in untreated patients with severe 
hypertension (DBP   110 mmHg) or patients with a DBP 
of  100 mmHg while receiving antihypertensive mono-
therapy.46 Patients initially received placebo for 1 week 
after which all patients with a DBP of  110 mmHg were 
randomized 2:1 to receive FD irbesartan/HCTZ or irbesartan 
monotherapy (as active control). FD irbesartan/HCTZ was 
initiated at a dose of 150/12.5 mg and force-titrated to 
300/25 mg at the end of the ﬁ  rst week of treatment (n = 468), 
while irbesartan was initiated at a dose of 150 mg and force-
titrated to 300 mg (n = 227). Therapy at the higher dose was 
given for 6 weeks.
At Week 5, signiﬁ  cantly more patients on combination 
therapy achieved a DBP of  90 mm Hg (the primary end-
point) compared with monotherapy recipients (47.2% vs 
33.2%; p = 0.0005). Similarly, the percentage of patients 
achieving dual BP goals (SBP/DPB   140/90 mmHg) was 
signiﬁ  cantly greater for FD irbesartan/HCTZ: 34.6% vs 
19.2%, p   0.0001 (Table 1). Indeed, a signiﬁ  cant difference 
in achievement of the DBP goal was evident after only 1 week 
of therapy (15.2% vs 9.2%, p = 0.03). In addition, the mean 
reduction in SBP/DBP was greater with FD combination 
therapy; at Week 5, the mean difference between combina-
tion and monotherapy in DBP and SBP was 4.7 mmHg and 
9.7 mmHg, respectively (p   0.0001). Thus initial therapy 
with FD irbesartan/HCTZ achieved more rapid BP reduc-
tions than irbesartan monotherapy in patients with severe 
hypertension, and in so doing signiﬁ  cantly reduced their 
exposure to severe hypertension.
Of the patients included in the RAPiHD severe study, 
approximately a quarter (n = 199, 29%) had SBP   180 mmHg 
at baseline. Analysis of data for this subgroup of patients showed 
that a reduction in SBP/DBP of 41/23 mmHg was achieved with 
combination therapy at Week 5 compared with 29/19 mmHg 
with monotherapy (p   0.0001 for SBP and p = 0.0071 for 
DBP).47 In addition, as early as 1 week after the start of therapy, 
more than 70% of patients receiving combination therapy were 
no longer in the stage 3 hypertension category.
The RAPiHD moderate study enrolled patients with 
moderate hypertension, deﬁ  ned as SBP of 160 to 179 mmHg 
and DBP of  110 mmHg in untreated patients; or SBP   150 
to  180 mmHg and DBP   95 to  110 mmHg in patients 
uncontrolled on monotherapy.48 Following a 3-week placebo 
washout period, patients were randomized 3:1:1 to irbesartan/
HCTZ 300/25 mg (n = 328), irbesartan 300 mg monotherapy 
(n = 106) or HCTZ monotherapy 25 mg (n = 104). Treatment 
was initiated at half dose, with forced titration to full dose 
after 2 weeks followed by 10 further weeks of treatment. 
The primary efﬁ  cacy endpoint was the change in SBP after 
8 weeks of active therapy.
FD irbesartan/HCTZ was found to induce a signiﬁ  cantly 
greater reduction in SBP and DBP than either monotherapy. 
The mean reduction in SBP was 27.1 mmHg with irbesartan/
HCTZ, compared with 22.1 mmHg with irbesartan monother-
apy (p = 0.0016) and 15.7 mmHg with HCTZ (p   0.0001), 
while the mean reductions in DBP from baseline to Week 8 
were 14.6 mmHg in the irbesartan/HCTZ group compared 
with 11.6 mmHg in the irbesartan group (p = 0.0013) and 
7.3 mm Hg in the HCTZ group (p   0.0001). Both the rate 
of decline and the total degree of decline achieved were 
greatest with irbesartan/HCTZ and least with HCTZ. In addi-
tion, a signiﬁ  cantly greater percentage of patients reached a 
treatment goal of SBP   140 mmHg and DBP   90 mmHg 
by Week 8 with irbesartan/HCTZ (53.4%), compared 
with irbesartan (40.6%; p = 0.0254) and HCTZ (20.2%; 
p   0.0001) alone (Table 1). Thus FD irbesartan/HCTZ 
treatment achieved more rapid BP reduction than irbesartan 
monotherapy or HCTZ monotherapy in patients with moder-
ate hypertension.
A post hoc pooled analysis of data from both this study 
and the randomized study in patients with severe hyperten-
sion found that the need for initial combination therapy 
increased with increasing baseline BP and lower BP goals 
across a range of BP levels spanning moderate and severe 
hypertension (Figure 1).49 For example, the probability of 
achieving a post-treatment value of  140 mmHg for a patient 
with a baseline SBP of 185 mm Hg was approximately 30% 
with irbesartan/HCTZ and 16% with irbesartan monotherapy, 
while for patients with a baseline SBP of 160 mmHg, the 
respective probabilities were 66% and 48%.
Another post hoc pooled analysis of data from both 
of these studies reported that SBP/DBP reductions 
(27–31/16–22 mmHg) were similar regardless of age, obesity, 
and type 2 diabetes status (Figure 2).50 SBP/DBP reductions 
with FD irbesartan/HCTZ were, however, greater in high- vs 
low-risk patients (30.4/22.1 mmHg vs 28.4/15.6 mmHg). 
When adjusted for factors including baseline age, BMI, 
type 2 diabetes, sex, race, cholesterol, target organ damage, 
and acute coronary syndrome, mean reductions in SBP were Vascular Health and Risk Management 2009:5 219
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Figure 1 Probability of achieving a SBP  140 mmHg at   Weeks 7/8 across a range of baseline SBP following treatment with irbesartan/hydrochlorothiazide (HCTZ), irbesartan, 
and HCTZ. Results from the RAPiHD study. Reproduced with permission from Franklin S, Lapuerta P, Cox D, Donovan M. Initial combination therapy with irbesartan/
hydrochlorothiazide for hypertension: an analysis of the relationship between baseline blood pressure and the need for combination therapy.  J Clin Hypertens (Greenwich). 2007; 
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Figure 2 Mean reductions from baseline in SBP and DBP following initial ﬁ  xed-dose irbesartan/hydrochlorothiazide (HCTZ) 300/25 mg treatment, according to age, body 
mass index (BMI), type 2 diabetes, and cardiovascular (CV) risk. Results from the RAPiHD study. Reproduced with permission from Weir MR, Neutel JM, Bhaumik A, Obaldia 
ME, Lapuerta P.   The efﬁ  cacy and safety of initial use of irbesartan/hydrochlorothiazide ﬁ  xed-dose combination in hypertensive patients with and without high cardiovascular 
risk.  J Clin Hypertens (Greenwich). 2007; 9(12 Suppl):23–30.60 Copyright © 2007 John Wiley and Sons, Inc.Vascular Health and Risk Management 2009:5 220
Bramlage
signiﬁ  cantly higher in patients aged 65 years or older than in 
those younger than 65 years (24.6 vs 21.0 mmHg; difference, 
3.6 mmHg; p = 0.015).
Taken together, the results from the 2 RAPiHD studies 
indicate the value of starting treatment with FD irbesartan/
HCTZ in patients with moderate or severe hypertension.
Studies on the effectiveness of irbesartan/
HCTZ in primary care
Further evidence for the efﬁ  cacy of FD irbesartan/HCTZ 
for the treatment of hypertension in patients uncontrolled on 
monotherapy and as initial therapy in patients with moderate 
or severe hypertension comes from the results of a Chinese 
study, several observational studies and two post-marketing 
studies.
A multicenter, open-label, single-arm study in Chinese 
patients has reported on the efﬁ  cacy of FD irbesartan/HCTZ 
in patients (n = 968) with mild-to-moderate hypertension.51 
Patients received FD irbesartan/HCTZ 150/12.5 mg for the 
ﬁ  rst 2 weeks and the dose was increased to 300/12.5 mg (after 
2 weeks) and 300/25 mg (after 4 weeks) if required to achieved 
a DBP of  85 mmHg. Treatment was given for 8 weeks. 
Of the patients who completed the study, 69% received 
irbesartan/HCTZ 150/12.5 mg, 23% received the interme-
diate dose level (300/12.5 mg) and 8% received the highest 
dose level (300/25 mg). After 8 weeks, a mean reduction in 
SBP/DBP of 22.0/16.1 mmHg was achieved (p   0.01) and 
BP control was achieved in 84% of patients.
Two German studies have reported on the beneﬁ  ts of 
irbesartan/HCTZ in patients with hypertension and diabetes. 
In one observational study involving 9057 patients with 
hypertension and diabetes, the improvement in BP control 
was assessed over a 6-month period in patients receiving 
irbesartan or irbesartan/HCTZ.52 At baseline, only 20% of 
patients had SBP levels within target (ie,  140 mmHg) 
and 57% had DBP levels within target (ie,  90 mmHg). 
However, at 6 months, BP control rates had improved to 63% 
for SBP and 93% for DBP. In the second observational study, 
patients with hypertension and type 2 diabetes (n = 31793) 
were switched from previous antihypertensive therapy to 
irbesartan (38%) or irbesartan/HCTZ (61%).53 Effects on BP 
were assessed after 3 months on irbesartan therapy. Mean 
SBP and DBP were reduced by 22.5 mmHg and 10.7 mmHg, 
respectively, while SBP normalization (SBP   140 mmHg) 
and DBP normalization (DBP   90 mmHg) was achieved 
in 43% and 74% of patients, respectively. In addition, 
mean albuminuria decreased by 27.7 mg/dL. The results 
of these 2 observational studies thus conﬁ  rm the beneﬁ  t of 
irbesartan/HCTZ in patients with hypertension and diabetes 
reported in the INCLUSIVE study and suggest that irbesartan 
and irbesartan/HCTZ can help achieve good BP control rates 
in routine clinical practice.
Further evidence for the beneﬁ  ts of FD irbesartan/HCTZ 
in daily clinical practice comes from a 3-month, prospec-
tive, open-label, multicenter, phase IV study of irbesartan 
or irbesartan/HCTZ in 72,479 hypertensive patients (92% 
of whom were overweight or obese) in 6989 general prac-
tices across Germany.54 Over the course of the 3-month 
study, a mean reduction in SBP/DBP of 23/12 mmHg was 
achieved and 48% of patients achieved BP normalization 
(SDP/DBP  140/90 mmHg). In addition, 79% of patients 
met their individual treatment goals, as deﬁ  ned by their 
physician.
Finally, another study has assessed the effect of irbesartan 
and irbesartan/HCTZ on BP in 14,200 patients with uncon-
trolled hypertension with or without the MS.55,56 Both irbesar-
tan and irbesartan/HCTZ produced signiﬁ  cant reductions in 
SBP/DBP over the 9-month study period (irbesartan mono-
therapy, 26.8/13.3 mmHg, p   0.0001; irbesartan/HCTZ, 
27.9/14.2 mmHg, p   0.0001), and BP normalization was 
achieved by 66% of patients receiving monotherapy and 79% 
of those receiving irbesartan/HCTZ. Approximately two-
thirds (n = 9281, 65%) of patients included in the study had 
MS. Reductions in SBP/DBP achieved with monotherapy and 
combination therapy in this subgroup of patients were similar 
to those for the total study population (irbesartan mono-
therapy, 26.3/13.0 mmHg, p   0.0001; irbesartan/HCTZ: 
27.5/14.1 mmHg, p   0.0001). Reductions in cardiovascular 
risk factors were also observed in patients with MS.
The results from these large multicenter studies provide 
further evidence for the beneﬁ  ts of irbesartan/HCTZ in the 
management of BP, both in patients with hypertension alone 
and those with other cardiovascular risk factors including 
diabetes, MS and obesity.
Clinical signiﬁ  cance of SBP/DBP 
reductions
The results of these studies show that irbesartan/HCTZ, used 
either to uptitrate from HCTZ monotherapy or as initial com-
bination therapy, is highly effective for reducing SBP/DBP 
and achieving SBP/DBP goals. Achievement of such SBP/
DBP reductions can be expected to translate into signiﬁ  cant 
improvements in clinical endpoints.57 Analysis of data from 
29 randomized trials including 162,341 patients, showed 
that the risk of major cardiovascular events was reduced by 
interventions to reduce BP and that greater risk reductions Vascular Health and Risk Management 2009:5 221
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were produced by antihypertensive regimens that targeted 
lower BP goals.57 In addition to the beneﬁ  ts associated with 
BP reductions, there is evidence to suggest that early achieve-
ment of BP reductions can produce greater reductions in 
stroke risk compared with delayed reductions, as observed 
in the VALUE (Valsartan Antihypertensive Long-term Use 
Evaluation) study.58 Analysis of data from this study showed 
that achieving BP control (SBP   140 mmHg) within the ﬁ  rst 
6 months of the study was associated with signiﬁ  cant beneﬁ  ts 
for subsequent major outcomes, including the risk of fatal 
and nonfatal cardiac events, fatal and nonfatal stroke, and 
all-cause death. In addition, achieving a BP response after 
just 1 month of treatment (deﬁ  ned as having no increase in 
BP in patients switched from previous therapy or achieving 
a decrease in SBP of  10 mmHg in previously untreated 
patients) predicted for a reduced risk of cardiac and stroke 
events, and improved survival. This suggests that the rapid 
achievement of BP goals with FD ARB/HCTZ combinations 
is likely to signiﬁ  cantly improve clinical endpoints compared 
with initial therapy with monotherapy.
Safety and tolerability of irbesartan/
HCTZ combination
It is well established that both HCTZ and irbesartan are well 
tolerated, and further studies have demonstrated that the addi-
tion of irbesartan to HCTZ and vice versa does not increase 
the incidence of adverse events. For example, in the 8-week 
study of Kochar et al22 in which patients received ﬁ  xed com-
binations of irbesartan (0, 37.5, 100 or 300 mg) plus HCTZ 
(0, 6.25, 12.5, or 25 mg), there was no signiﬁ  cant difference 
in the incidence of commonly occurring adverse events 
between placebo, irbesartan monotherapy or irbesartan/
HCTZ combination therapy, and no dose-related adverse 
events were observed. Indeed, for a number of common 
adverse events, such as headache, irbesartan monotherapy 
and irbesartan/HCTZ were associated with a lower incidence 
of events than placebo. Also, the addition of irbesartan to 
HCTZ reversed HCTZ-induced hypokalemic effects and the 
increases in serum uric acid levels seen with HCTZ.
The adverse event rates for the major trials with FD 
irbesartan/HCTZ are presented in Table 2. In the INCLUSIVE 
trial, FD irbesartan/HCTZ 150/12.5 mg and irbesartan/HCTZ 
300/25 mg were found to be well tolerated over the 18 weeks 
of therapy (Table 2).41 Only dizziness and hypotension 
occurred more frequently during treatment with irbesartan/
HCTZ than with placebo (dizziness: placebo, 1%; irbesartan/
HCTZ 150/12.5 mg, 2%; irbesartan/HCTZ 300/25 mg, 3%; 
hypotension: placebo, 0%; irbesartan/HCTZ 150/12.5 mg, 
0.1%; irbesartan/HCTZ 300/25 mg, 1%). No patients were 
discontinued from the study because of adverse events.
Safety and tolerability is a critical consideration in aggres-
sive hypertensive therapy which can be associated with 
hypotension, syncope, headache and hypokalemia. However, 
in patients with severe hypertension46 or with moderate 
hypertension,48 starting treatment with FD irbesartan/HCTZ 
was as well tolerated as starting with irbesartan monotherapy. 
The adverse event and discontinuation rates are given in 
Table 2. In patients with moderate hypertension, 7 of the 
Table 2 Safety data for main studies of ﬁ  xed-dose irbesartan/hydrochlorothiazide (FD irbesartan/HCTZ): incidence of adverse events
  FD irbesartan/HCTZ Irbesartan
monotherapy
Study in patients failing monotherapy (INCLUSIVE)41 n = 844
Any adverse event 27% irbesartan/HCTZ 150/12.5 mg 
26% irbesartan/HCTZ 300/25 mg
Serious adverse event 1% irbesartan/HCTZ 150/12.5 mg; 
1% irbesartan/HCTZ 300/25 mg
Initial therapy in patients with severe hypertension46 n = 695
Any adverse event 30% 36%
Discontinuation due to adverse event 1.9% 2.2%
Serious adverse event 0.2% 0.4%
Initial therapy in patients with moderate hypertension48 n = 538
Any adverse event 47% 45%
Treatment-related adverse event 14% 11%
Discontinuation due to adverse event 6.7% 3.8%
Serious adverse event 1.8%a 0%
aOf the 6 serious adverse events, only 1 was treatment related.Vascular Health and Risk Management 2009:5 222
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22 patients receiving combination therapy withdrew due to 
dizziness or hypotension but these events occurred primar-
ily following forced titration in patients in whom BP was 
already controlled. 48 In patients with severe hypertension, 
there was no syncope reported during the study, and the 
incidence of hypotension was  1% in patients taking FD 
irbesartan/HCTZ combination therapy.46
In comparator trials, FD irbesartan/HCTZ had a similar 
adverse event proﬁ  le to losartan/HCTZ40 and valsartan/
HCTZ.39 Long-term safety data for patients receiving irbesar-
tan/HCTZ (although not as ﬁ  xed-dose combination therapy) 
also support the favorable safety proﬁ  le.33,34
In summary, accumulating safety data for irbesartan/
HCTZ combination therapy indicate that this ARB/ HCTZ 
antihypertensive combination is well tolerated by patients 
with hypertension; most adverse events are of mild or moder-
ate intensity and transient in duration. In general, there is no 
evidence of an increase in the incidence of adverse effects 
as therapy is uptitrated, with the possible exception of dizzi-
ness and hypotension. However, the overall incidence of all 
individual adverse events is low. The incidence of adverse 
events with irbesartan/HCTZ appears to be similar to that 
for irbesartan monotherapy, while compared with HCTZ 
monotherapy, irbesartan/HCTZ appears to be better tolerated. 
This reﬂ  ects the fact that HCTZ decreases serum potassium 
levels in a dose-related manner. However, this effect is less 
pronounced with the addition of increasing doses of irbesar-
tan, and irbesartan 300 mg appears to provide greatest beneﬁ  t 
in reversing the hypokalemic effects of HCTZ. In addition, 
HCTZ 25 mg results in a small increase in serum uric acid, 
but the addition of irbesartan reduces this effect. Thus no 
clinically signiﬁ  cant occurrences of electrolyte imbalance 
have been observed in trials with irbesartan/HCTZ combina-
tion therapy or with irbesartan monotherapy. In conclusion, 
irbesartan/HCTZ is well tolerated and has a similar safety 
proﬁ  le to that of irbesartan monotherapy.
Adherence and patient acceptance 
of FD irbesartan/HCTZ
Rapid and effective reduction of BP in hypertensive patients 
helps to prevent major cardiovascular events but patient non-
adherence to antihypertensive medication often hinders the 
attainment of their optimal BP goal, as already discussed. FD 
irbesartan/HCTZ offers the important advantage of reducing 
the number of tablets to be taken by a patient and may there-
fore be expected to improve compliance and hence the efﬁ  cacy 
of antihypertensive therapy over therapy with an ARB and 
HCTZ as separate tablets. Indeed the beneﬁ  ts of combination 
therapy in a single tablet over receiving medications as indi-
vidual tablets in terms of improved compliance have clearly 
been demonstrated in three studies of persistence with anti-
hypertensive therapy. One study retrospectively compared 
persistence for patients prescribed enalapril/HCTZ as a single 
pill or enalapril plus a diuretic as separate pills, and for patients 
prescribed lisinopril/HCTZ or lisinopril plus a diuretic as 
separate pills. At 12 months after the initial prescription, the 
percentage of patients persisting with therapy was 18.8% 
higher for lisinopril/HCTZ compared with lisinopril plus a 
diuretic and 21.7% higher for enalapril/HCTZ compared with 
enalapril plus a diuretic. These differences were statistically 
signiﬁ  cant (p   0.05). Two further studies have determined 
patient persistence with FD amlodipine/benazepril or an 
ACE-I plus a CCB.20,24 Gerbino et al20 reported a persistence 
rate of 87.9% for FD amlodipine/benazepril compared with 
69.2% for prescription of separate tablets, a difference that 
was statistically signiﬁ  cant (p   0.0001), while Dickson et al24 
also reported a statistically signiﬁ  cant difference in favor of 
FD combination therapy in their study in elderly patients 
(63.4% vs 49.0%, p   0.0001).
Conclusions
FD irbesartan/HCTZ has been shown to be effective for produc-
ing BP control in patients failing on antihypertensive monother-
apy and as initial therapy in patients with moderate or severe 
hypertension who often require multiple agents to achieve BP 
control. It is effective in patients with type 2 diabetes, MS, and 
elderly patients as well as younger patients, and the response 
is similar regardless of race/ethnicity. In patients with severe 
or moderate hypertension, initial treatment with FD irbesartan/
HCTZ achieves more rapid BP reductions than either agent as 
monotherapy and enables a greater proportion of subjects with 
severe hypertension to achieve BP targets. This is likely to be 
of signiﬁ  cant therapeutic beneﬁ  t in such patients since studies 
have shown that a more rapid achievement of BP reductions 
predicts for better cardiovascular outcomes. FD irbesartan/
HCTZ is well tolerated, as for irbesartan monotherapy, and 
appears to reduce the incidence of hypokalemia and raised 
serum uric acid levels observed with HCTZ. The ARB/HCTZ 
combination therapies have an important role in the manage-
ment of hypertension in clinical practice.
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